{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:19:15Z","timestamp":1791073155594,"version":"4.1.0"},"reference-count":101,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T00:00:00Z","timestamp":1392854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Over the past several years, hepatitis C therapy has been pegylated interferon and ribavirin based. Although protease inhibitor\u2010based therapy has enhanced response rates in genotype 1, the recent advances in therapy have demonstrated a challenge in genotype 3, a highly prevalent infection globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To provide a comprehensive summary of the literature evaluating the unique characteristics and evolving therapies in genotype 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A structured search in PubMed, the Cochrane Library and\n                      <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>\n                      was performed using defined key words, including only full text papers and abstracts in English.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      genotype 3 is more prevalent in Asia and among intra\u2010venous drug users. Furthermore, it interferes with lipid and glucose metabolism, and the natural history involves a more rapid progression of liver disease and a higher incidence of hepatocellular carcinoma (HCC). New therapies with protease inhibitors have focused on genotype 1 largely and have demonstrated enhanced responses, but have limited activity against genotype 3. Thus far, in clinical trials,\n                      <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>\n                      5B and\n                      <jats:styled-content style=\"fixed-case\">NS<\/jats:styled-content>\n                      5A inhibitors have performed more poorly in genotype 3, while a cyclophilin inhibitor, alisporivir, has shown promise.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      As treatments for\n                      <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                      have evolved, genotype 3 has become the most difficult to treat. Furthermore, genotype 3 has special characteristics, such as insulin resistance and alterations in lipid metabolism, which may partly explain the lower treatment responses. A great deal of emphasis on advancing therapy is needed in this population that appears to have a more rapid progression of liver disease and a higher incidence of HCC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.12646","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T12:31:59Z","timestamp":1393245119000},"page":"686-698","source":"Crossref","is-referenced-by-count":99,"title":["Review article:\n                    <scp>HCV<\/scp>\n                    genotype 3 \u2013 the new treatment challenge"],"prefix":"10.1111","volume":"39","author":[{"given":"J.","family":"Ampuero","sequence":"first","affiliation":[{"name":"Unit for the Clinical Management of Digestive Diseases and CIBERehd Valme University Hospital University of Seville Seville Spain"},{"name":"Division of Gastroenterology and Hepatology Department of Medicine University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romero\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Unit for the Clinical Management of Digestive Diseases and CIBERehd Valme University Hospital University of Seville Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Medicine University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Health Organization.Hepatitis C. Available at:http:\/\/www.euro.who.int\/en\/what-we-do\/health-topics\/communicable-diseases\/hepatitis. Accessed November 10 2013."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38965-8_6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.09.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2013.847089"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12168"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20819"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22127"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12551"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-8-69"},{"key":"e_1_2_9_14_1","first-page":"173","article-title":"Genotype distribution in chronic hepatitis C patients in Greece","volume":"58","author":"Stamouli M","year":"2012","journal-title":"Clin Lab"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2008.02.001"},{"key":"e_1_2_9_16_1","first-page":"109","article-title":"Genotype distribution amongst hepatitis C patients in The Netherlands","volume":"64","author":"Vries MJ","year":"2006","journal-title":"Neth J Med"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1607"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.1237"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00319.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20692"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.11.5240-5244.2003"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351621"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01523.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12234"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24432"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50267"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/524846"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80166-X"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01441.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.08.032"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.010"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.022"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04716.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.07.026"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12113"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63408-6"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hep.2003.09.012"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.020644-0"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.056"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12766"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2001.1225"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25631"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.10.019"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042608"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.04.042"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.004"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22253"},{"issue":"1","key":"e_1_2_9_52_1","first-page":"271A","article-title":"The outcome of 24 vs 48\u00a0weeks of peginterferon alfa\u20102a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N\u2010CORE study","volume":"56","author":"Cheinquer H","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_9_54_1","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa\u20102b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem S","year":"2004","journal-title":"J Hepatol"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03763.x"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01481.x"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.04.029"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26905"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01555.x"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.024"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(08)60776-X"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20467"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21975"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23531"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.008"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.04.009"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.05.046"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.018"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-405880-4.00005-6"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26371"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.08.019"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02715.x"},{"issue":"1","key":"e_1_2_9_77_1","first-page":"1425A","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for chronic HCV genotype\u20101 infection in treatment\u2010naive patients: results from QUEST\u20101, a phase III trial","volume":"58","author":"Jacobson I","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"e_1_2_9_78_1","first-page":"1413A","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype\u20101 infection in treatment\u2010naive patients: results from QUEST\u20102, a phase iii trial","volume":"58","author":"Manns M","year":"2012","journal-title":"J Hepatol"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.033"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.2174\/157489108784746597"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.826189"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)61417-8"},{"issue":"1","key":"e_1_2_9_83_1","first-page":"479A","article-title":"MK\u20108742, a HCV NS5A inhibitor with a broad potent antiviral activity in genotype\u20101 and \u20103 HCV\u2010infected patients","volume":"58","author":"Yeh W","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_9_84_1","first-page":"1082A","article-title":"GS\u20105816, a once\u2010daily NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1, 2, 3, or 4 HCV infection in a 3\u2010day monotherapy study","volume":"58","author":"Lawitz E","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.775246"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.855126"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"issue":"1","key":"e_1_2_9_88_1","first-page":"LB\u20104","article-title":"Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV\u2010Infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: results from the LONESTAR\u20102 Study","volume":"58","author":"Lawitz E","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(10)60039-6"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22131"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22835"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"issue":"1","key":"e_1_2_9_95_1","first-page":"1085A","article-title":"Sofosbuvir + Ribavirin for 12 or 24\u00a0weeks for patients with HCV genotype 2 or 3: the VALENCE study","volume":"58","author":"Zeuzem S","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_9_96_1","first-page":"309A","article-title":"Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)\u2010free or IFN\u2010add\u2010on regimen in treatment\u2010naive patients with HCV GT2 or GT3: final results from VITAL\u20101 study","volume":"56","author":"Pawlotsky JM","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_9_97_1","first-page":"792A","article-title":"Interferon\u2010free Alisporivir (DEB025) treatment in the VITAL\u20101 study has a more beneficial overall safety profile vs IFN\u2010containing treatment","volume":"56","author":"Griffel L","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61433-0"},{"issue":"1","key":"e_1_2_9_99_1","first-page":"1153","article-title":"Cyclophilin inhibitor Alisporivir combinations with direct acting antivirals reveal strong synergistic anti\u2010HCV effects","volume":"58","author":"Garcia\u2010Rivera J","year":"2013","journal-title":"J Hepatol"},{"key":"e_1_2_9_100_1","volume-title":"Sovaldi (sofosbuvir) tablets: US prescribing information","year":"2013"},{"key":"e_1_2_9_101_1","volume-title":"Olysio (simeprevir) capsules: US prescribing information","year":"2013"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12423"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12646","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:23:59Z","timestamp":1695554639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/apt.12646"],"URL":"https:\/\/doi.org\/10.1111\/apt.12646","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718304571.793492480","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}